{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-100228","form_type":"8-K","ticker":"TMDX","cik":"0001756262","company_name":"TransMedics Group, Inc.","filed_at":"2025-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.886665+00:00","generated_at":"2026-05-17T23:08:36.835072+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"TransMedics Q2 revenue $157.4M (+38% YoY), net income $34.9M; raises FY2025 guidance","bullets":["Revenue $157.4M vs $114.3M YoY (+38%); net income $34.9M ($0.92 diluted EPS) vs $12.2M.","Raises full-year 2025 revenue guidance to $585M-$605M from $565M-$585M (35% midpoint growth).","Gross margin 61% consistent YoY; operating expenses $60.0M up from $56.8M on R&D investment.","Cash $400.6M; received conditional IDE approval from FDA for Next-Gen OCS Lung trial.","Launched OCS NOP digital ecosystem NOP ACCESS across major U.S. transplant programs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-100228","json":"https://secwatch.observer/filing/0000950170-25-100228.json","markdown":"https://secwatch.observer/filing/0000950170-25-100228.md","text":"https://secwatch.observer/filing/0000950170-25-100228.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1756262/000095017025100228/0000950170-25-100228-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1756262/000095017025100228/tmdx-20250730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:08:36.835072+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}